Palisade Bio (NASDAQ:PALI) Posts Quarterly Earnings Results, Beats Expectations By $1.03 EPS

Posted by Tech Dows on Nov 15th, 2024

Palisade Bio (NASDAQ:PALI – Get Free Report) issued its earnings results on Tuesday. The company reported ($2.32) earnings per share for the quarter, beating the consensus estimate of ($3.35) by $1.03, Zacks reports.

Palisade Bio Stock Performance

PALI stock traded up $0.42 during trading on Thursday, reaching $2.62. 100,518 shares of the company were exchanged, compared to its average volume of 408,717. The stock’s 50 day moving average price is $3.35 and its 200 day moving average price is $4.20. The company has a market cap of $3.48 million, a P/E ratio of -0.19 and a beta of 1.36. Palisade Bio has a 52-week low of $2.18 and a 52-week high of $22.35.

Analyst Ratings Changes

Separately, Maxim Group lowered their price objective on Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a report on Wednesday.

Check Out Our Latest Analysis on PALI

Palisade Bio Company Profile

(Get Free Report)

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.